Comparison of predicted AMIO drug interactions versus observed clinical DDIs for drugs primarily metabolized by CYP1A2, CYP2C9, CYP2D6, or CYP3A4

Predicted interactions are based on the sum of [I]u/Ki,u data (eq. 1) determined for the reversible inhibition of specific P450 substrate probes by AMIO and its circulating human metabolites (Table 1).

PharmaceuticalIn Vivo DDI (AUCi/AUC)Predicted DDI
Lidocaine1.21 (Ha et al., 1996)1.28
S-Warfarin2.10 (O’Reilly et al., 1987)1.89
Metoprolol1.94 (Werner et al., 2004)1.64
Simvastatin1.76 (Becquemont et al., 2007)1.35
R-Warfarin1.62 (O’Reilly et al., 1987)1.35
  • AUC, area under the time versus plasma drug concentration curve.